Scholarly article on topic 'Crude Extracts from Lycium barbarum Suppress SREBP-1c Expression and Prevent Diet-Induced Fatty Liver through AMPK Activation'

Crude Extracts from Lycium barbarum Suppress SREBP-1c Expression and Prevent Diet-Induced Fatty Liver through AMPK Activation Academic research paper on "Biological sciences"

Share paper
Academic journal
BioMed Research International
OECD Field of science

Academic research paper on topic "Crude Extracts from Lycium barbarum Suppress SREBP-1c Expression and Prevent Diet-Induced Fatty Liver through AMPK Activation"

Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 196198, 10 pages

Research Article

Crude Extracts from Lycium barbarum Suppress SREBP-1c Expression and Prevent Diet-Induced Fatty Liver through AMPK Activation

Wang Li,1 Yan Li,1 Qing Wang,1 and Yi Yang1,2

1 Biochemistry and Molecular Biology, Ningxia Medical University, Yinchuan 750004, China

2 Key Laboratory of Fertility Preservation and Maintenance of Ministry of Education, Ningxia Medical University, Yinchuan 750004, China

Correspondence should be addressed to Yi Yang;

Received 27 March 2014; Revised 13 May 2014; Accepted 20 May 2014; Published 10 June 2014

Academic Editor: Koichiro Wada

Copyright © 2014 Wang Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lycium barbarum polysaccharide (LBP) is well known in traditional Chinese herbal medicine that, has beneficial effects. Previous study reported that LBP reduced blood glucose and serum lipids. However, the underlying LBP-regulating mechanisms remain largely unknown. The main purpose of this study was to investigate whether LBP prevented fatty liver through activation of adenosine monophosphate-activated protein kinase (AMPK) and suppression of sterol regulatory element-binding protein-1c (SREBP-1c). Male C57BL/6J mice were fed a low-fat diet, high-fat diet, or 100mg/kg LBP-treatment diet for 24 weeks. HepG2 cells were treated with LBP in the presence of palmitic acid. In our study, LBP can improve body compositions and lipid metabolic profiles in high-fat diet-fed mice. Oil Red O staining in vivo and in vitro showed that LBP significantly reduced hepatic intracellular triacylglycerol accumulation. H&E staining also showed that LBP can attenuate liver steatosis. Hepatic genes expression profiles demonstrated that LBP can activate the phosphorylation of AMPK, suppress nuclear expression of SREBP-1c, and decrease protein and mRNA expression of lipogenic genes in vivo or in vitro. Moreover, LBP significantly elevated uncoupling protein-1 (UCP1) and peroxisome proliferator-activated receptor-y coactivator-1a (PGC-1a) expression of brown adipose tissue. In summary, LBP possesses a potential novel treatment in preventing diet-induced fatty liver.

1. Introduction

An imbalance between energy intake and expenditure can cause the excessive accumulation of triacylglycerol in tissues of eukaryotic organisms [1, 2]. The accumulation of triacyl-glycerol in adipose tissue can result in obesity and in nonadi-pose tissues, especially liver tissue, which are associated with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD) [3, 4]. High-fat diet-induced fatty liver is characterized by excessive accumulation of triacylglycerol in the liver, also impairs fatty acid oxidation, and increases hepatic de novo lipogenesis [4-6]. Furthermore, long-term high-fat diet-induced dysregulation of hepatic lipid metabolism increases lipolysis, causing an increase in free fatty acid levels [7]. These metabolic changes trigger fatty liver and lead to systemic aggravation of lipid metabolic dysfunction [8].

Sterol regulatory element-binding protein-1c (SREBP-1c) is the key regulator of lipid metabolism on nutritional status. Activation of SREBP-1c increases hepatic lipogene-sis under high dietary conditions and leads to fatty liver [9]. Conversely, activation of adenosine monophosphate-activated protein kinase (AMPK) has been shown to reduce lipogenesis in the liver by inhibiting SREBP-1c expression and further prevent the development of fatty liver [10]. Thus, some pharmacologic agents that inhibit SREBP-1c expression via stimulating AMPK activity in hepatocytes may provide more effective treatment options for fatty liver disease.

Previous studies have found that LBP was able to improve lipid metabolism profiles in animal and human models. For example, LBP clearly decreased serum total cholesterol (TC), triacylglycerol (TG), and high-density lipoprotein (HDL)

in hyperlipidemic animal [11]. The clinical study provided evidence that LBP could play an important role in treating hyperlipidemic patients [12]. However, the underlying mechanisms of the hepatoprotective effects of LBP remain largely unknown. Our aim of this study is determine whether LBP has a protective effect against diet-induced fatty liver. To further explore and evaluate antilipid effects of LBP on the expression of SREBP-lc-mediated lipogenic genes involved in triacylglycerol synthesis through AMPK-dependent pathway were investigated in a model of diet-induced fatty liver in vivo and in vitro.

2. Material and Methods

2.1. Preparation of Lycium barbarum Polysaccharide (LBP). LBP was extracted from L. barbarum as previously described [13]. Briefly, the dried fruit of L. barbarum was put in boiling deionized water. The water extract was filtered through a filter paper to remove impurities. The crude extract was concentrated to the volume under vacuum at 40°C and diluted to deionized water. Then the extract was precipitated with 95% ethanol, followed by centrifugation to remove the supernatant. Then the precipitate was collected and ground into powder. The powder of LBP was dissolved in normal saline for mice experiment, filtered through a 0.22 ^m filter, and stored at -20°C.

2.2. Animals and Diets. Male C57BL/6J mice from Beijing Vital River Biological Co., Ltd. were housed in standard cage conditions (temperature: 22 ± 1° C; relative humidity: 56 ± 5°C) at a 12/12 light/dark cycle. All mice had free access to diet and water for 2 weeks. Mice were divided into three groups (n = 10 per group): low-fat diet (LFD) (D12450B, USA), high-fat diet (HFD) (D12492, USA), and HFD plus LBP (100 mg/kg). Low-fat diet contains 10% of Kcal as fat with an energy density of 3.85 Kcal per gram, while high-fat diet contains 60% of Kcal as fat with an energy density of 5.24 Kcal per gram. We observed body weight, food intake, water intake, and blood glucose every week. We calculated food intake according to the following formula: food intake (g/d mouse) = the total food intake (g/per week)/[7 (d) x 5 (mice/cage)]. We calculated energy consumption according to the following formula provided by the research diets: energy consumption (Kcal/d mouse) = 3.85 or 5.24 (Kcal/g) x food intake (g/d mouse). All mice were deprived of diet and fasted for overnight at 24 weeks. Blood samples were collected from the eyeballs of mice and placed for 10 min at room temperature. Serum was obtained by centrifuging at 3,000 r for 15min at 4°C and stored at -80°C. Liver and brown adipose tissue were isolated, frozen in liquid nitrogen, and stored at -80°C. The animal experiments were approved by the Animal Research Committee of Ningxia Medical University, China.

2.3. Cell Culture and Treatment. HepG2 cells (Peking University, China) were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 30 mM glucose, 10% fetal

bovine serum (Gibco, USA), and 1% penicillin and streptomycin (Invitrogen, CA, USA) in 5% CO2 at 37°C. The cells were pretreated with 250 ^M palmitate (Sigma) for 12 h and then treated with 30-600 ^g/mL LBP for 12 h.

2.4. Biochemical Analysis. The serum biochemical profiles, including TG, TC, AST, ALT, HDL, and LDL, were determined using a Biochem-Immunoautoanalyser (Brea, CA, USA). Glucose levels were determined with a glucometer (Accu-Chek; Roche Diagnostics). NEFA and DAG levels of the serum and liver tissue were measured with mouse ELISA kit (CUSABIO) according to the manufacturer's instructions. Triacylglycerol of liver tissue was measured with the triacyl-glyceride assay kit (Applygen Technologies Inc., China).

2.5. Histological Analysis. Liver tissue was fixed in 4% paraformaldehyde buffer, embedded in paraffin, and cut at 5 ^m sections. Liver sections were stained with hematoxylin and eosin (H&E). The assessment of liver histology was previously described [14]. To further confirm lipid droplet accumulation, seeded cells and frozen liver sections were stained with Oil Red O.

2.6. Immunohistochemistry. The sections were prepared as described for H&E staining. Immunohistochemistry was performed using the following primary antibodies: anti-rabbit-SREBP-1c and -FAS antibody and then stained with goat anti-rabbit IgG-HRP as secondary antibody. The reactivity of the antibodies was detected using a DAB horseradish peroxidase color development kit. The sections were counterstained with hematoxylin and observed with a microscope (Olympus IX71).

2.7. RNA Isolation and Semiquantitative and Quantitative RT-PCR. Total RNA was extracted from liver tissue using TRIzol reagent (Invitrogen). RNA concentrations were determined by SmartSpec Plus (BIO-RAD, USA). 1 ^g of total RNA was transcribed to cDNA using the superscript first-strand synthesis kit (Thermo) following instructions. UCP1 and PGC-1a expression were analyzed using semiquantitative RT-PCR. The cDNA was served as a template in a 50 ^L reaction mixture and was processed using an initial step at 94° C for 5min, followed by 32 amplification cycles (94°C for 30 s, 55°C for 30 s, and 72°C for 35 s), and 72°C for 5min. Primers were as follows: UCP1 (forward, 5'-GGTTTTGCACCACACTCCTG-3'; reverse, 5'-ACATGGACATCGCACAGCTT-3'), PGC-1a (forward, 5'-TAAATCTGCGGGATGATGGA-3'; reverse, 5'-GTTTCGTTCGACCTGCGTAA-3'), and GAPDH (forward, 5'-AGAACATCATCCCTGCATCC-3'; reverse, 5'-TCCACCACCCTGTTGCTGTA-3'). Quantitative RT-PCR analysis was performed with a LightCycler instrument (Roche Applied Science) and SYBR green detection of amplified products. Primers for SREBP-1c, ACC, FAS, CPT-1a, and CD36 were previously described [15]. PCR reactions were performed in triplicate and normalized to cyclophilin using the 2-AACt method.

Table 1: Effect of LBP on body compositions of HFD-fed mice.

Variables LFD HFD 100 LBP + HFD

Initial body weight (g) 23.1 ±0.23 23.8 ± 0.29 23.6 ± 0.23

Final body weight (g) 30.0 ± 0.46 44.6 ± 1.01 33.5 ± 1.43*

Water intake (mL/d/mouse) 6.97 ±0.16 8.41 ±0.17 7.26 ± 0.05

Abdominal circumference (cm) 7.63 ±0.13 10.83 ±0.08 7.98 ±0.14*

BMI (g/cm2) 0.32 ± 0.07 0.58 ±0.10 0.37 ±0.09*

Liver weight (g) 1.06 ± 0.04 2.31 ±0.18 1.25 ±0.05*

White fat weight (g) 0.71 ± 0.06 4.40 ± 0.22 1.66 ± 0.08**

Brown fat weight (g) 0.24 ± 0.03 0.09 ± 0.01 0.30 ± 0.05**

Data are expressed as means ± SEM (n = 10 per group), *P < 0.05 and **P <0.01, compared to HFD group. LFD: low-fat diet; HFD: high-fat diet; 100 LBP +

HFD: 100 mg/kg LBP plus high-fat diet; BMI: body mass index.

Table 2: Effect of LBP on serum lipid profile of HFD-fed mice.

Variables LFD HFD 100 LBP + HFD

Blood glucose (mmol/L) 3.82 ±0.15 9.66 ±0.19 5.02 ± 0.26**

Total cholesterol (mmol/L) 1.24 ± 0.56 2.09 ± 1.14 1.38 ± 2.04*

HDL-cholesterol (mmol/L) 0.41 ± 0.03 0.28 ± 0.03 0.58 ± 0.09*

LDL-cholesterol (mmol/L) 0.13 ±0.12 0.55 ± 0.25 0.28 ± 0.46*

AST (U/L) 78.4 ± 8.70 244.6 ± 12.45 141.7 ± 5.26**

ALT (U/L) 68.6 ± 3.83 129.3 ±6.36 78.2 ±5.18**

NEFA (umol/L) 244 ± 10.8 480 ± 26.5 261 ± 33.6***

Data are expressed as means ± SEM (n = 10 per group), *P < 0.05, **P < 0.01, and ***p < 0.001, compared to HFD group. HDL: high-density lipoprotein; LDL: low-density lipoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; NEFA: nonesterified fatty acids.

2.8. Western Blot. Whole and nuclear proteins were extracted from liver and HepG2 cells as described previously [10]. Protein concentration was quantified with the BCA method according to the supplier's instructions (Sigma). 50 ^g of protein was added to 8% SDS-PAGE and electroblotted onto PVDF membranes (Pall Corporation, Pensacola). The membranes were blocked and incubated with specific antibodies against AMPK, AMPK (pThr172), FAS, ACC (pSer79), and ACC (cell signaling technology) and SREBP-1c, ^-actin, and Lamin A/C (Santa Cruz Biotechnology). Consequently, the membranes were incubated with the corresponding horseradish peroxidase goat anti-rabbit IgG-HRP or anti-mouse IgG-HRP as secondary antibody (Santa Cruz Biotechnology). The immunoreactive proteins were detected with enhanced chemiluminescence (Pierce Biotechnology, USA). Band intensities were scanned (Epson Perfection V33) and quantified using the Image J software.

2.9. Statistical Analysis. All results were expressed as means ± SEM. Data was analyzed using the ANOVA multiple comparison test (SPSS 13.0). P < 0.05 was considered to be statistically significant.

3. Results

3.1. Body Compositions Analysis. In the whole study, body weight, water intake, and food intake, which play a central role in HFD feeding mice, were monitored during the experiment. LBP significantly reduced body weight compared with HFD-fed mice (Figures 1(a) and 1(b) and Table 1,

P < 0.05). There was no significance for food intake, energy consumption, and water intake between their groups (Figures 1(c) and 1(d) and Table 1). Abdominal circumference and BMI of LBP-treatment mice were significantly reduced as shown in Table 1 (P < 0.05). Liver weights and total white fat weights of HFD-fed mice were higher than the weights of LFD-fed mice and were reduced when mice were treated with LBP (Figure 2(a) and Table 1, P < 0.05 and P < 0.01). Moreover, LBP increased brown fat storages of HFD-fed mice (Table 1, P < 0.05). As shown in Figures 2(b) and 2(c), histological analysis of liver sections showed that LBP obviously lowered liver steatosis index compared to HFD-fed group (P < 0.001).

3.2. Serum Biochemistry Analysis. To further evaluate the effect of LBP-treatment mice, we measured serum TG, TC, HDL, LDL, AST, ALT, and NEFA. As shown in Table 2, serum concentrations of TC and LDL were all significantly lower in LBP-treatment mice than in HFD-fed mice, while HDL level was reversed in LBP-treatment mice (P < 0.05). LBP-treatment group had meaningful reduced NEFA levels compared to the HFD-fed group (P < 0.05). ALT and AST were also lower in LBP-treatment group than in HFD-fed group (P < 0.01). LBP also reduced blood glucose levels of the whole body of HFD-fed mice (P < 0.01). As shown in Table 3, we found that TG and DAG levels of serum and liver were significantly reduced in LBP-treatment group compared to that in HFD-fed group (P < 0.05). As expected, these data showed that treatment of LBP was valuable for improving

Figure 1: Effect of LBP on the whole statue of HFD-fed mice. (a) Gross contour of the whole body and visceral fat among four groups of mice for 24 weeks. (b) Changes in body weight every two weeks (« = 10 per group). *P < 0.05, compared to HFD group. (c) Food intake and (d) energy consumption. Data was expressed as mean ± SEM (« = 10 per group). NS: no significance. Note: food intake (g/d mouse) = the total food intake (g/per week)/[7 (d) x 5 (mice/cage)]; energy consumption (Kcal/d mouse) = 3.85 or 5.24 (Kcal/g) x food intake (g/d mouse).

Table 3: Effect ofLBP on DAG and TG levels of serum and liver of HFD-fed mice.

Variables LFD HFD 100 LBP + HFD

DAG Serum (pmol/L) Liver (nmol/g) 3.16 ±0.08 0.59 ±0.09 6.27 ± 0.50 1.03 ± 0.03 3.50 ±0.34* 0.57 ±0.07*

TG Serum (mmol/L) Liver (mg/g) 0.84 ±0.16 2.2 ±0.56 1.83 ± 0.27 5.6 ± 0.97 1.02 ± 0.48* 2.8 ±0.55*

Data are expressed as mean ± SEM (n = 10 per group), *P < 0.05, compared to HFD group. DAG: diacylglycerol; TG: triacylglycerol.

the whole body composition and serum lipid profiles in HFD feeding mice.

3.3. LBP Activated the Phosphorylation of AMPK and Suppressed Nuclear SREBP-1c In Vivo and In Vitro. We assessed hepatic levels of phospho-AMPK, nuclear SREBP-1c, phospho-ACC, and FAS in vivo and in vitro experiments. Mice fedHFD hadpotentlyincreased hepaticlevelsofnu clear

SREBP-1c and FAS and decreased hepatic phosphorylation levels of AMPK and ACC. On the contrary, LBP significantly reversed HFD-induced alterations in hepatic levels of these proteins (Figures 3(a) and 5(a), P < 0.05 and P < 0.01). SREBP-1c and FAS staining showed cytoplasmic expression levels in liver, respectively (Figure 3(c)).

3.4. LBP Prevented Fatty Liver through AMPK/SREBP-1c Pathway. We analyzed the mRNA levels of genes involved in lipogenesis and fatty acid p-oxidation. Our results showed that mRNA levels of SREBP-1c, ACC, and FAS were increased in the HFD group compared to the LFD group. In contrast, LBP significantly reduced mRNA expression of these genes (Figure 4(a), P < 0.05 and P < 0.01). Interestingly, compared with mice fed HFD, LBP significantly elevated CPT-1a level and inhibited CD36 level (Figure 4(b), P < 0.05 and P < 0.01). Oil Red O staining in vivo and in vitro showed the same tendency in which LBP significantly reduced hepatic intracellular TG accumulation (Figures 2(d) and 5(b)). Taken together, LBP suppressed lipogenesis and stimulated fatty

Figure 2: LBP reverses liver steatosis in HFD-fed mice. (a) Appearance of liver and percentage of hepatic mass. Data was expressed as mean ± SEM (n = 10 per group). *P < 0.05, compared to HFD group. (b) Liver steatosis index. ***P < 0.001, compared to HFD group. (c) Representative photos of H&E-stained liver sections (x400 magnification). (d) Representative photos of Oil Red O-stained liver frozen sections (x200 magnification).

acid ^-oxidation via AMPK/SREBP-1c pathway, reduced hepatic TG accumulation, and prevented fatty liver.

3.5. LBP Increased UCP1 and PGC-1a Expression of Brown Fat Tissue. We evaluated genes expression of UCP1 and PGC-1a. As shown in Figure 3(a), the mRNA levels of UCP1 and PGC-1a showed great differences between the three groups. The expressions of UCP1 and PGC-1a in HFD-fed mice were higher than that of ND-fed mice. LBP significantly enhanced

these genes' expression of brown fat tissue in HFD-fed mice (P < 0.05).

4. Discussion

The mice model of high-fat diet-induced fatty liver was considered a good model for the study of metabolic syndrome [16, 17]. In our study, HFD-fed mice had obviously increased body and liver weights, serum concentrations of


nSREBP-1c Lamin A/C p-AMPK AMPK p-ACC ACC FAS ß-Actin




^rn HFD

I-1 100LBP + HFD

2.5 -,


'LFD • *i . • " - - I *• * ■ , 25 um HFD * * •», „ i * * * * ■ * • * . ..*•■• -■ • ■ if ' ■ . 25 .* . »JR. >.. •. '. - ■

t • 'i ¿«•■'A' 1 • * . ' ••I »- .* •,• - « J. Mi? ;-: , ,, , . " . ■ • - ' \ ',■». ' ■ ' l*»1* ■. ■ . . .•* - £ - . ■■.■■: v." ■ _25^m


/25 ^m,

Figure 3: LBP prevents fatty liver by activation of AMPK and inhibition of SREBP-1c in HFD-fed mice. (a) Protein expression levels of p-AMPK, nuclear SREBP-1c, p-ACC, and FAS in liver tissue. Data was normalized to ^-actin, *P < 0.05, and **P < 0.01, compared to HFD group, respectively. (b) The mRNA expression of UCP1 and PGC-1a in brown adipose tissue. Data was normalized to GAPDH and *P < 0.05, compared to HFD group, respectively. (c) Immunohistochemical analysis detected the distribution of SREBP-1c and FAS in liver sections (x400 magnification).

JS 1 ■


4-, ACC

2.0 —


(a) Lipogenesis 3

■X 4 A

^ 3 _ < 3-1


100LBP + HFD


100LBP + HFD

(b) ^-Oxidation

Figure 4: LBP improves the imbalance between lipogenesis and fatty acid ^-oxidation via downregulation of SREBP-lc expression in HFD-fed mice. (a) Relative genes mRNA expression of lipogenesis and (b) fatty acid ^-oxidation. Data was normalized to GAPDH, *P < 0.05, and **P < 0.01, compared to HFD group, respectively.

TG, DAG, TC, LDL, NEFA, AST, and ALT, and liver concentrations of TG and DAG. On the contrary, LBP significantly decreased body and liver weights as well as serum and liver lipid concentrations. LBP also attenuated the development of HFD-induced fatty liver as assessed by histochemical analysis. These data demonstrated that LBP possesses biological activities for the regulation of lipid metabolism and fatty liver development in the liver.

Although the molecular mechanism causing the development of fatty liver in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) is complex, animal models have shown that modulating important enzymes, such as ACC and FAS, in fatty acid synthesis in liver may be a key for the treatment of NAFLD [18-20]. Recent studies in humans and in rodents have demonstrated that an increase in de novo hepatic lipogenesis plays a pivotal role in HFD-induced excessive hepatic fat accumulation [21, 22]. The in vivo and in vitro experiment showed overexpression of HFD-induced

ACC and FAS was substantially suppressed by LBP. Hepatic expression of SREBP-lc, which plays a major role in fatty liver, is responsible for these genes in the liver [20, 2325] and affects the lipid accumulation induced by high-fat diet [26, 27]. Our study showed that HFD-fed or palmitate-pretreatment mice stimulated hepatic expression of SREBP-lc at protein and mRNA levels in vivo and in vitro. However, SREBP-lc is regulated by multiple factors, including insulin [28], AMPK [10,28,29], and liver X receptors (LXR) [20,29]. It has been shown that AMPK activators, including alpha-lipoic acid [30] and metformin [31], inhibit the SREBP-lc expression and prevent the development of fatty liver. Our results support such a mechanism, showing that suppression of SREBP-lc expression by LBP is mediated by stimulation of AMPK activity. Taken together, LBP regulates hepatic genes responsible for de novo fatty acid synthesis via modulation of AMPK/SREBP-lc pathway and diminishes HFD-induced fatty liver.

Palmitate (250 ^M) 0 30 100 300 600



si 3 -p

tila 1


□ Control □ 100 ■ 0 ■ 300

□ 30 ■ 600

Palmitate (250uM^(rt| 4

30 ^g/mL LBP + palmitate (250 ^M)

100 ^g/mL LBP + palmitate (250 ^M) 300 ^g/mL LBP + palmitate (250 ^ 600 ^g/mL LBP + palmitate (250 ^M)

10 ^m 10 ^m 10 ^m

Figure 5: LBP reduces intracellular triacylglycerol accumulation via activation of AMPK and suppression of SREBP-lc in HepG2 cells. (a) HepG2 cells were pretreated with 250 ^M palmitate for 12 h andthen treated with30-600 ^g/mL LBP for 12 h. Western blot analyzed p-AMPK, nuclear SREBP-lc, p-ACC, and FAS expression. Data was normalized to ^-actin and *P < 0.05, compared to HFD group, respectively. (b) Representative photos of Oil Red O-stained HepG2 cells (x1000 magnification).

CPT-1a is a major enzyme that catalyzes fatty acid ß-oxidation [32], while CD36 promotes a combination of lipid storage and lipogenesis [23, 33]. HFD-induced fatty liver further aggravated fatty acid ^-oxidation system and impaired the balance of lipid metabolism [34]. Our study indicated that hepatic ^-oxidation was indeed reduced in the HFD group. In contrast, treatment of LBP increased CPT-1a mRNA level and decreased CD36 mRNA level. These results

suggested that the beneficial effects of LBP in the treatment of fatty liver may be partly due to improved fatty acid p-

oxidation in the liver.

White adipose tissue (WAT) increases production and release of fatty acids and, in turn, leads to a fatty liver [35]. Unlike WAT, brown adipose tissue (BAT), an essential component of energy expenditure, expends energy by heat production through uncoupling protein-1 (UCP-1) and

peroxisome proliferator-activated receptor-y coactivator-1a (PGC-1a) in its mitochondria [36]. This change of HFD-induced downregulation of UCP-1 and PGC-1a in the brown adipocytes causes morphologic and metabolic conversion to the white adipocytes [35, 37, 38]. As expected, LBP significantly reversed the HFD-induced downregulation of UCP-1 and PGC-1a of brown adipose tissue. Therefore, it is possible that LBP activating or elevating the expression of UCP-1 and PGC-1a would have crucial effect on increasing the energy expenditure to ultimately prevent fatty liver, which in turn protects liver function.

5. Conclusion

In conclusion, our present results, for the first time, demonstrate that LBP ameliorates HFD-induced fatty liver in vivo and in vitro, in which modulation of the hepatic AMPK/SREBP-lc pathway plays a pivotal role. Our finding may provide better understanding of LBP and associated chemicals and herbs in the treatment of liver disorders, especially nonalcoholic fatty liver disease.


ACC: Acetyl-CoA carboxylase

CD36: Cluster of differentiation 36

CPT-la: Carnitine palmitoyltransferase la

DAG: Diacylglycerol

FAS: Fatty acid synthetase

HFD: High-fat diet

LBP: Lycium barbarum polysaccharide

NAFLD: Nonalcoholic fatty liver disease

LFD: Low-fat diet

NEFA: Nonesterified fatty acid

PGC-la: Peroxisome proliferator-activated

receptor-y coactivator-la SREBP-1c: Sterol regulatory element-binding

protein-1c UCP1: Uncoupling protein-1.

Conflict of Interests

The authors declare that they have no conflict of interests.


This study was supported by National Nature Science Foundation of China (81160103) and Science Research and International Cooperation Project of Ningxia Hui Autonomous Region (NXIC2011010).


[1] J.-A. Kim, Y. Wei, and J. R. Sowers, "Role of mitochondrial dysfunction in insulin resistance," Circulation Research, vol. 102, no. 4, pp. 401-414, 2008.

[2] J.-Q. Chen, T. R. Brown, and J. Russo, "Regulation of energy metabolism pathways by estrogens and estrogenic chemicals and potential implications in obesity associated with increased

exposure to endocrine disruptors," Biochimica et Biophysica Acta: Molecular Cell Research, vol. 1793, no. 7, pp. 1128-1143,

[3] E. Fabbrini, S. Sullivan, and S. Klein, "Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications," Hepatology, vol. 51, no. 2, pp. 679-689, 2010.

[4] C. A. Nagle, E. L. Klett, and R. A. Coleman, "Hepatic triacyl-glycerol accumulation and insulin resistance," Journal of Lipid Research, vol. 50, pp. S74-S79, 2009.

[5] P. J. Raubenheimer, M. J. Nyirenda, and B. R. Walker, "A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet," Diabetes, vol. 55, no. 7, pp. 2015-2020, 2006.

[6] N. Anderson and J. Borlak, "Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis," Pharmacological Reviews, vol. 60, no. 3, pp. 311-357, 2008.

[7] I. W. Asterholm and P. E. Scherer, "Enhanced metabolic flexibility associated with elevated adiponectin levels," The American Journal of Pathology, vol. 176, no. 3, pp. 1364-1376, 2010.

[8] K. Qureshi and G. A. Abrams, "Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease," World Journal of Gastroenterology, vol. 13, no. 26, pp. 3540-3553, 2007.

[9] M. S. Strable and J. M. Ntambi, "Genetic control of de novo lipogenesis: role in diet-induced obesity," Critical Reviews in Biochemistry and Molecular Biology, vol. 45, no. 3, pp. 199-214,

[10] Y. Li, S. Xu, M. M. Mihaylova et al., "AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice," Cell Metabolism, vol. 13, no. 4, pp. 376-388, 2011.

[11] Q. Luo, Y. Cai, J. Yan, M. Sun, and H. Corke, "Hypoglycemic and hypolipidemic effects and antioxidant activity of fruit extracts from Lycium barbarum," Life Sciences, vol. 76, no. 2, pp. 137-149, 2004.

[12] H. Amagase, B. Sun, and C. Borek, "Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults," Nutrition Research, vol. 29, no. 1, pp. 19-25,2009.

[13] C. L. Lin, C. C. Wang, S. C. Chang, B. S. Inbaraj, and B. H. Chen, "Antioxidative activity of polysaccharide fractions isolated from Lycium barbarum Linnaeus," International Journal of Biological Macromolecules, vol. 45, no. 2, pp. 146-151, 2009.

[14] D. E. Kleiner, E. M. Brunt, M. Van Natta et al., "Design and validation of a histological scoring system for nonalcoholic fatty liver disease," Hepatology, vol. 41, no. 6, pp. 1313-1321, 2005.

[15] F. Benhamed, P.-D. Denechaud, M. Lemoine et al., "The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans," Journal of Clinical Investigation, vol. 122, no. 6, pp. 2176-2194, 2012.

[16] M.-S. Choi, M.-K. Lee, U. J. Jung et al., "Metabolic response of soy pinitol on lipid-lowering, antioxidant and hepatoprotective action in hamsters fed-high fat and high cholesterol diet," Molecular Nutrition and Food Research, vol. 53, no. 6, pp. 751759, 2009.

[17] F. Briand, Q. Thiéblemont, E. Muzotte, and T. Sulpice, "High-fat and fructose intake induces insulin resistance, dyslipidemia, and liver steatosis and alters in vivomacrophage-to-feces reverse cholesterol transport in hamsters," Journal of Nutrition, vol. 142, no. 4, pp. 704-709, 2012.

[18] T. Matsuzaka and H. Shimano, "Molecular mechanisms involved in hepatic steatosis and insulin resistance," Journal of Diabetes Investigation, vol. 2, no. 3, pp. 170-175, 2011.

[19] A. Ferramosca and V. Zara, "Modulation of hepatic steatosis by dietary fatty acids," World Journal of Gastroenterology, vol. 20, no. 7, pp. 1746-1755, 2014.

[20] C. Postic and J. Girard, "Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice," Journal of Clinical Investigation, vol. 118, no. 3, pp. 829-838, 2008.

[21] Q. M. Anstee and R. D. Goldin, "Mouse models in non-alcoholic fatty liver disease and steatohepatitis research," International Journal of Experimental Pathology, vol. 87, no. 1, pp. 1-16, 2006.

[22] M.-Y. Park and S. T. Mun, "Dietary carnosic acid suppresses hepatic steatosis formation via regulation of hepatic fatty acid metabolism in high-fat diet-fed mice," Nutrition Research and Practice, vol. 7, no. 4, pp. 294-301, 2013.

[23] J. Zhou, Y. Zhai, Y. Mu et al., "A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway," Journal of Biological Chemistry, vol. 281, no. 21, pp. 15013-15020, 2006.

[24] A. K. Stoeckman and H. C. Towle, "The role of SREBP-1c in nutritional regulation of lipogenic enzyme gene expression," Journal of Biological Chemistry, vol. 277, no. 30, pp. 2702927035, 2002.

[25] C. Postic and J. Girard, "The role of the lipogenic pathway in the development of hepatic steatosis," Diabetes and Metabolism, vol. 34, no. 6, pp. 643-648, 2008.

[26] R. Du, J. Xue, H.-B. Wang, Y. Zhang, and M.-L. Xie, "Osthol ameliorates fat milk-induced fatty liver in mice by regulation of hepatic sterol regulatory element-binding protein-1c/2-mediated target gene expression," European Journal of Pharmacology, vol. 666, no. 1-3, pp. 183-188, 2011.

[27] C. Zhang, X. Chen, R.-M. Zhu et al., "Endoplasmic reticulum stress is involved in hepatic SREBP-1c activation and lipid accumulation in fructose-fed mice," Toxicology Letters, vol. 212, no. 3, pp. 229-240, 2012.

[28] M. Kohjima, N. Higuchi, M. Kato et al., "SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease," International Journal of Molecular Medicine, vol. 21, no. 4, pp. 507-511, 2008.

[29] F. Yap, L. Craddock, and J. Yang, "Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription," International Journal of Biological Sciences, vol. 7, no. 5, pp. 645-650, 2011.

[30] K.-G. Park, A.-K. Min, E. H. Koh et al., "Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monopho-sphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways," Hepatology, vol. 48, no. 5, pp. 1477-1486, 2008.

[31] E.-J. Jung, S.-W. Kwon, B.-H. Jung, S.-H. Oh, and B.-H. Lee, "Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver," Journal of Lipid Research, vol. 52, no. 9, pp. 1617-1625, 2011.

[32] S. Vankoningsloo, M. Piens, C. Lecocq et al., "Mitochondrial dysfunction induces triglyceride accumulation in 3T3-L1 cells: role of fatty acid ^-oxidation and glucose," Journal of Lipid Research, vol. 46, no. 6, pp. 1133-1149, 2005.

[33] S. Santosa and M. D. Jensen, "Adipocyte fatty acid storage factors enhance subcutaneous fat storage in postmenopausal women," Diabetes, vol. 62, no. 3, pp. 775-782, 2013.

[34] R. Yanagisawa, E. Koike, T. T. Win-Shwe, M. Yamamoto, and H. Takano, "Impaired lipid and glucose homeostasis in hexabromocyclododecane-exposed mice fed a high-fat diet,"

Environmental Health Perspectives, vol. 122, no. 3, pp. 277-283, 2014.

[35] J. D. Horton, I. Shimomura, S. Ikemoto, Y. Bashmakov, and R. E. Hammer, "Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver," Journal of Biological Chemistry, vol. 278, no. 38, pp. 3665236660, 2003.

[36] S. Suqimoto, H. Nakajima, K. Kodo et al., "Miglitol increases energy expenditure by upregulating uncoupling protein 1 of brown adipose tissue and reduces obesity in dietary-induced obese mice," Nutrition and Metabolism, vol. 11, no. 1, article 14, 2014.

[37] S.-W. Qian, Y. Tang, X. Li et al., "BMP4-mediated brown fatlike changes in white adipose tissue alter glucose and energy homeostasis," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 9, pp. E798-E807, 2013.

[38] J. Auffret, S. Viengchareun, N. Carre et al., "Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-dietinduced obesity," The FASEB Journal, vol. 26, no. 9, pp. 3728-3737, 2012.

Copyright of BioMed Research International is the property of Hindawi Publishing Corporation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.